<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9810">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05689697</url>
  </required_header>
  <id_info>
    <org_study_id>KetonicPharm</org_study_id>
    <nct_id>NCT05689697</nct_id>
  </id_info>
  <brief_title>Induced Physiological Ketosis in Asthenia and\or Decreased Tolerance to Physical and\or Mental Exertion</brief_title>
  <official_title>Efficacy of Physiological Ketosis Induced by Liquid Technology Formula PanTrek in Asthenia and\or Decreased Tolerance to Physical and\or Mental Exertion (Double-blind, Placebo-controlled Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ketonic Pharm LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ketonic Pharm LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is evaluating of efficacy of innovative dietary strategy&#xD;
      -stimulation of physiological ketosis with Liquid Technology Formula PanTrek, in patients&#xD;
      with asthenia and or decreased tolerance to physical and\or mental exertion. PanTrek is a&#xD;
      liquid formula of potassium and magnesium salts of beta-oxibutiric acid, ginsenosides and&#xD;
      rosmarinic acid.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It will be double-blind, placebo-controlled study in 88 patients of both sex, aged from 18 to&#xD;
      65. Patients will be randomly assigned to one of two groups: placebo or IP group in 1:1&#xD;
      proportion. Study instruments: D-Fis, MoCA, TMT, VAS, assessment of blood keton concentration&#xD;
      before and after first and last administration per os of 25 ml of placebo or PanTrek. PanTrek&#xD;
      will be served in ampuls, 25 ml per ampule.&#xD;
&#xD;
      The duration of the study will be 15 days of treatment and 15 days of follow-up observation.&#xD;
&#xD;
      Patients will be assessed at screening/baseline, after 15 days and after 30 days.&#xD;
&#xD;
      The dose regimen: the shot of PanTrek, 25 ml, will be administered per os, twice per day, in&#xD;
      the morning and in the evening, per se or deluted in 100 ml of water one hour before or after&#xD;
      meal.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 9, 2023</start_date>
  <completion_date type="Anticipated">August 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>randomized asignment to placebo or IP group, double-blind design</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Primary outcome</measure>
    <time_frame>15 days</time_frame>
    <description>Difference of changes of visual analog scale (VAS) indices between active treament and placebo groups. Minimum value - 0, maximum value - 100 scores. The higher score means the better condition. The major difference means better outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>indused ketosis</measure>
    <time_frame>15 days</time_frame>
    <description>increase of ketons level from baseline to the end of the active treatment period of the study</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Improvement in cognitive function</measure>
    <time_frame>15 days</time_frame>
    <description>Difference in improvement in total scores of Montreal Cognitive Assessment (MoCA) between the treatment and placebo groups. Minimum value - 0, maximum value - 30 scores. The higher score means the better condition. The major difference means better outcome.</description>
  </other_outcome>
  <other_outcome>
    <measure>Improvement in visual attention and task switching.</measure>
    <time_frame>15 days</time_frame>
    <description>Difference in improvement of total time of Trial Making Test (TMT) execution between the treatment and placebo groups. Normal value - 29 seconds for A part and 75 seconds for B part. The higher time means worse condition. Decrease of spended time means improvement or negative score, if the last result is substractes from the first result, means improvement.</description>
  </other_outcome>
  <other_outcome>
    <measure>Improvement in physical function</measure>
    <time_frame>15 days</time_frame>
    <description>Difference in improvement in total scores of Daily Fatigue Investigation Scale (D-Fis) between the treatment and placebo groups. Minimum value - 0, maximum value - 32 scores. The higher score means the worse condition. The major difference means better outcome.</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety profile in active and follow-up period</measure>
    <time_frame>30 days</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 on the first, 15th and 30th day.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Patient Activation</condition>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will recieve matched by taste and color shot of 25 ml liquid in ampules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will recieve shot of PanTrek 25 ml in anpules</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>PanTrek</intervention_name>
    <description>administration of exogenouse keton body</description>
    <arm_group_label>Active treatment group</arm_group_label>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  informed consent&#xD;
&#xD;
          -  diagnosis of astenia and/or decreased tolerance to physical and\or mental exertion&#xD;
&#xD;
          -  ability of patients to understand assessment procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  intollerance of components of PanTrek&#xD;
&#xD;
          -  participation in other trials&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denis Burminskiy, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Mental health research center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Denis Burminskiy, MD, PhD</last_name>
    <phone>+79262344633</phone>
    <email>desbur@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Allan Beniashvili, MD, PhD</last_name>
    <phone>+79859259676</phone>
    <email>beniashvilia@yandex.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Laboratory of psychopharmacology Research center of mental health</name>
      <address>
        <city>Moscow</city>
        <zip>115522</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <contact>
      <last_name>Denis Burminsiy, MD, PhD</last_name>
      <phone>+79262344633</phone>
      <email>desbur@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Allan Beniashvili, MD, PhD</last_name>
      <phone>+79859259676</phone>
      <email>beniashvilia@yandex.ru</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>December 2022</verification_date>
  <study_first_submitted>December 23, 2022</study_first_submitted>
  <study_first_submitted_qc>January 10, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2023</study_first_posted>
  <last_update_submitted>January 10, 2023</last_update_submitted>
  <last_update_submitted_qc>January 10, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Physiological Ketosis</keyword>
  <keyword>PanTrek</keyword>
  <keyword>Asthenia</keyword>
  <keyword>Physical functioning</keyword>
  <keyword>Mental functioning</keyword>
  <keyword>beta-oxibutiric acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketosis</mesh_term>
    <mesh_term>Asthenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

